Exelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberBusiness Wire • 11/07/24
Exelixis (EXEL) Reliance on International Sales: What Investors Need to KnowZacks Investment Research • 11/04/24
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth EngineSeeking Alpha • 10/31/24
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 10/29/24
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateBusiness Wire • 10/29/24
5 Biotech Stocks Likely to Outperform as Industry Prospects Look BrightZacks Investment Research • 10/24/24
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024Business Wire • 10/15/24
Exelixis Announces Update on Second Patent Litigation Trial with MSN LaboratoriesBusiness Wire • 10/15/24
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCZacks Investment Research • 10/15/24
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell CarcinomaBusiness Wire • 10/14/24